Log In Sign up
The largest database of trusted experimental protocols

Foretinib

Manufactured by LC Laboratories
Visit Supplier
Sourced in United States

Foretinib is a small molecule inhibitor that targets multiple receptor tyrosine kinases, including MET, VEGFR2, RON, and AXL. It is a laboratory research product intended for use in scientific investigations.

Automatically generated - may contain errors

Lab products found in correlation

Az628, by Selleck Chemicals (2 mentions) Motesanib, by LC Laboratories (2 mentions) Tivozanib, by Selleck Chemicals (2 mentions) Bafetinib, by Selleck Chemicals (2 mentions) Braf inhibitor 1, by ChemScene (2 mentions) Rebastinib, by ChemScene (2 mentions) Doramapimod, by Selleck Chemicals (2 mentions) Bms 777607, by Selleck Chemicals (2 mentions) Wst 1, by Merck Group (1 mentions) Acetonitrile, by Merck Group (1 mentions) Milli q plus purification system, by Merck Group (1 mentions) Lapatinib, by MedChemExpress (1 mentions) Formic acid, by Merck Group (1 mentions) Rat liver microsomes, by Merck Group (1 mentions) Masitinib, by LC Laboratories (1 mentions)

4 protocols using foretinib

1

Nab-Paclitaxel and Foretinib Proliferation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Nab‐paclitaxel (Celgene Corporation, Summit, NJ) was procured from the Goshen Center for Cancer Care Pharmacy (Goshen, IN). Foretinib was purchased from LC Laboratories (Woburn, MA). The cell proliferation reagent WST‐1 was purchased from Sigma‐Aldrich.
Grojean M., Schwarz M.A., Schwarz J.R., Hassan S., von Holzen U., Zhang C., Schwarz R.E, & Awasthi N. (2021). Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. Journal of Cellular and Molecular Medicine, 25(11), 4950-4961.
+ Open protocol
+ Expand
2

Procuring Validated Type II Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine structurally validated type II
inhibitors, which are commercially available, were procured form chemical
vendors. Foretinib and motesanib free bases were obtained from LC
Laboratories. Doramapimod, bafetinib, tivozanib, BMS-777607, and AZ-628
were obtained from Selleck Chem. BRAF inhibitor 1 and rebastinib were
obtained from Chemscene. The compounds obtained had an average purity
of >96%.
Vijayan R.S., He P., Modi V., Duong-Ly K.C., Ma H., Peterson J.R., Dunbrack RL J.r, & Levy R.M. (2014). Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of Medicinal Chemistry, 58(1), 466-479.
+ Open protocol
+ Expand
3

Procurement of Validated Type II Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine structurally validated type II inhibitors, which are commercially available were procured form chemical vendors. Foretinib and Motesanib free bases were obtained from LC Laboratories. Doramapimod, Bafetinib, Tivozanib, BMS-777607 and AZ-628 were obtained from Selleck Chem. BRAF inhibitor 1 and Rebastinib were obtained from Chemscene. The compounds obtained had an average purity > 96%.
Vijayan R.S., He P., Modi V., Duong-Ly K.C., Ma H., Peterson J.R., Dunbrack RL J.r, & Levy R.M. (2014). Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of Medicinal Chemistry, 58(1), 466-479.
+ Open protocol
+ Expand
4

Lapatinib, Foretinib, and Masitinib Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All reagents and solvents were of analytical grade. Lapatinib was purchased from Med Chem Express (USA). Foretinib (FTB) and masitinib (MST) were purchased from LC Laboratories (USA). Acetonitrile (ACN), Rat liver microsomes (RLMs), and formic acid (HCOOH) were purchased from Sigma-Aldrich (USA). HPLC-grade water was obtained from the Milli-Q plus purification system (Millipore, USA).
Alanazi M.M., Alkahtani H.M., Almehizia A.A., Attwa M.W., Bakheit A.H, & Darwish H.W. (2019). Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation. RSC Advances, 9(34), 19325-19332.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!